These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 34556152)
21. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma. Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119 [TBL] [Abstract][Full Text] [Related]
22. Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model. Mori JI; Adachi K; Sakoda Y; Sasaki T; Goto S; Matsumoto H; Nagashima Y; Matsuyama H; Tamada K Cancer Sci; 2021 Apr; 112(4):1417-1428. PubMed ID: 33539630 [TBL] [Abstract][Full Text] [Related]
23. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042 [TBL] [Abstract][Full Text] [Related]
24. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741 [TBL] [Abstract][Full Text] [Related]
25. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells. Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741 [TBL] [Abstract][Full Text] [Related]
27. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer. Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298 [TBL] [Abstract][Full Text] [Related]
28. Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen. Adotévi O; Galaine J Cancer Res; 2022 Jul; 82(14):2517-2519. PubMed ID: 35844172 [TBL] [Abstract][Full Text] [Related]
29. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752 [No Abstract] [Full Text] [Related]
30. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774 [TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284 [TBL] [Abstract][Full Text] [Related]
32. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594 [TBL] [Abstract][Full Text] [Related]
33. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691 [TBL] [Abstract][Full Text] [Related]
34. Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma. Wu S; Wang B; Li H; Wang H; Du S; Huang X; Fan Y; Gao Y; Gu L; Huang Q; Chen J; Zhang X; Huang Y; Ma X Oncogene; 2024 May; 43(20):1534-1548. PubMed ID: 38548966 [TBL] [Abstract][Full Text] [Related]
35. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038 [TBL] [Abstract][Full Text] [Related]
36. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471 [TBL] [Abstract][Full Text] [Related]
37. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. Tykodi SS; Satoh S; Deming JD; Chou J; Harrop R; Warren EH J Immunother; 2012 Sep; 35(7):523-33. PubMed ID: 22892449 [TBL] [Abstract][Full Text] [Related]
38. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells. Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533 [TBL] [Abstract][Full Text] [Related]
39. Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma. Xu DD; Ding M; Tong P; Chong YY; Gu WY; Li Y; Fang XJ; Li N Oncol Rep; 2020 Sep; 44(3):897-908. PubMed ID: 32705278 [TBL] [Abstract][Full Text] [Related]
40. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway. Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]